Valby, Denmark, 4 December 2018 - H. Lundbeck A/S (Lundbeck) today announced that Anders Gersel Pedersen, Executive Vice President and Head of Research and Development (R&D), will retire after 19 years with the company. Anders Gersel’s retirement will be effective as of 31 December 2018.
"After 19 years at Lundbeck and seven years as Head of R&D I have decided to retire, even though I know that I will miss working with a great leadership team and committed and competent employees," said Anders Gersel Pedersen. "It has been an honor to lead the R&D organization and our dedicated team of employees to advance the treatment of patients suffering from CNS disorders. I am proud of all we have achieved together.”
"Throughout his tenure at Lundbeck, Anders has strived to transform Lundbeck’s R&D into an organization with the potential to be one of the best within CNS disorders," said Deborah Dunsire, President and Chief Executive Officer of Lundbeck. "I thank Anders for his leadership, innovation and dedication to Lundbeck over the past two decades and wish him all the best for the future."
Anders Gersel Pedersen joined Lundbeck in 2000 as Vice President of International Clinical Research. Anders was later appointed Executive Vice President of Drug Development and in 2011 appointed responsible for all Research & Development activities at Lundbeck.
Anders is a member of the European Society of Medical Oncology, the International Association for the Study of Lung Cancer, the American Society of Clinical Oncology, the Danish Society of Clinical Oncology and the Danish Society of Internal Medicine. He also serves on the Board of Directors at Bavarian Nordic A/S (Deputy Chairman), Hansa Medical AB and Genmab A/S.
Lundbeck has initiated a comprehensive international search to identify the company’s next EVP, Head of R&D.
Palle Holm Olesen
Vice President, Investor Relations
Senior Director, Corp. Communication
+45 30 83 24 26
+45 36 43 40 00
About H. Lundbeck A/S
H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in psychiatric and neurological disorders. For more than 70 years, we have been at the forefront of research within neuroscience. Our key areas of focus are Alzheimer's disease, depression, Parkinson's disease and schizophrenia.
Our approximately 5,000 employees in 55 countries are engaged in the entire value chain throughout research, development, manufacturing, marketing and sales. Our pipeline consists of several late-stage development programs and our products are available in more than 100 countries. We have production facilities in Denmark, France and Italy. Lundbeck generated revenue of DKK 17.2 billion in 2017 (EUR 2.3 billion; USD 2.6 billion).
For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us on Twitter at @Lundbeck.
Safe Harbor/Forward-Looking Statements
The above information contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions, product approvals and financial performance.
Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include interest rate and currency exchange rate fluctuations, delay or failure of development projects, production problems, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Lundbeck's products, introduction of competing products, Lundbeck's ability to successfully market both new and existing products, exposure to product liability and other lawsuits, changes in reimbursement rules and governmental laws and related interpretation thereof, and unexpected growth in costs and expenses.
Certain assumptions made by Lundbeck are required by Danish Securities Law for full disclosure of material corporate information. Some assumptions, including assumptions relating to sales associated with product that is prescribed for unapproved uses, are made taking into account past performances of other similar drugs for similar disease states or past performance of the same drug in other regions where the product is currently marketed. It is important to note that although physicians may, as part of their freedom to practice medicine in the US, prescribe approved drugs for any use they deem appropriate, including unapproved uses, at Lundbeck, promotion of unapproved uses is strictly prohibited.